Tumour agnostic therapy demonstrates sustained efficacy
Tumour agnostic therapy demonstrates sustained efficacy
Concerns over NHS Test and Trace system exacerbated by continuing rise in cases
The drug is the first and only therapy for the ultra rare condition Familial Chylomicronaemia Syndrome (FCS)
The deadline for entering the 2020 PharmaTimes Communications Awards, Sales Awards and Marketer of the Year competitions has been extended to Friday October 2 after a last-minute spike in enquiries
Industry body says in vitro diagnostics are vital to clearing the backlog of undiagnosed conditions
Over half of patients treated with combination therapy were alive and relapse-free after five years
AZ will take the programme forward into clinical development
Middle dose tested hit the primary endpoint of the Phase II trial
People with sleep condition could be at an increased risk of adverse outcomes from COVID-19
Researchers found combination treatment showed promise against a range of cancer types
Lumevoq is designed to treat vision loss associated with Leber Hereditary Optic Neuropathy
World Evidence-based Healthcare Day takes place on 20 October
Report also highlights the impact of COVID-19 on the physical and mental health of doctors
Pharmacists, GPs and patients join arms to call for law change
Agreement grants MSD access to investigational ADC and a small molecule tyrosine kinase inhibitor